Aeterna Zentaris Bumps BPH Therapy Cetrorelix To Front Of Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
With a projected NDA filing in Q1 2010, firm plans to position the LHRH antagonist’s favorable sexual side effect profile compared to agonists such as top-selling Flomax.
You may also be interested in...
Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate
Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.
Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate
Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.
Aeterna Shifts Directions Again; CEO And Senior VP Depart
Interim CEO says Canadian biotech will continue development of prostate cancer drug and seek to divest additional non-core assets.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: